Background: It remains uncertain whether vitD3 supplementation is beneficial for remission of Crohn's disease (CD). The influence of vitD3 supplementation on Infliximab (IFX) efficacy was retrospectively analyzed in Chinese CD patients. Methods: Patients with moderate-to-severe CD, who were bio-naïve and prescribed with IFX treatment for at least 54 weeks were recorded. VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period. Disease activity was assessed using Harvey-Bradshaw Index (HBI). Serum cytokine profiles were quantitatively analyzed in a subset of all patients at baseline and 54-week after intervention.
Study Type
OBSERVATIONAL
Enrollment
70
VitD3 supplementation was defined as patients additionally took oral vitD3 (125 IU/d) within 3 days after the first infusion and persisted in the whole follow-up period.
SAHWenzhouMU
Wenzhou, Zhejiang, China
Serum 25 (OH) D level
Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status.
Time frame: 54 weeks
disease activity
CDAI evaluation
Time frame: 54 weeks
the metabolism of calcium and phosphorus
serum levels calcium and phosphorus
Time frame: 54 weeks
the expression profiles of Th-cell-related cytokines
Serum levels of IL-2, IL-4, IL-6, IL-10, TNF-α and IFN-γ
Time frame: 54 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.